xCELLigence CardioECR

xCELLigence CardioECR

Hersteller ACEA Biosciences Inc.

Artikel-Nr.: 2801190

Accessories for xCELLigence Systems

Brochures & Applications

Preis auf Anfrage


Die mit einem * markierten Felder sind Pflichtfelder.



xCELLigence CardioECR

A Comprehensive Solution for in vitro Cardiac Safety Assessment 
The xCELLigence RTCA CardioECR System is the first ever platform to combine impedance and field potential recording for simultaneous and noninvasive measurement of integrated ion channel activity and contractility of cardiomyocytes in a 48 well microtiter plate format. The system is designed to be placed in a standard tissue culture incubator with physiological temperature, CO2 level and humidity, allowing better controlled assays with both short-term and long-term measurements in real-time.

xCELLigence CardioECR - simultaneous Real-Time Measurement

  • Assessment of ion channel (Na+, Ca2+, K+) activities
  • Detection of arrhythmic events
  • Measurement of contractility
  • User defined pacing of cardiomyocytes
  • (Long term) Assessment of cardiomyocyte viability


MEA and Pacing key features to elucidate mechanisms of toxicity
With the added MEA capabilities and pacing stimuli, the new CardioECR System allows for a deeper assessment of mechanism of toxicity. Field potential recording provided by MEA electrodes is a measure of the integrated ion channel activity that may be impacted by the tested compound, whreas the pacing function allows for controllin the rate of contractility for a more controlled assay. Furthermore, this combined dual readout system also provides a longer-term measurement of cardiomyocyte viability which can potentially identify those compounds causing longer-term structural damage to cardiomyocytes.

Key Features

  • Real-time: short (hrs) and long-term (days) assay
  • High throughput conduct MEA and impedance assay simultaneously on 48-well format
  • Pacing function: 100% pacing success rate across the plate
  • Tri-mode:
  • - RTCA mode - determination of cell growth status over the assay time
  • - Cardio mode - observation of cardiac beating activity over the assay time
  • - CardioECR mode - simultaneous recording of cardio beating activity and electric activity (field potential) over the assay time


Real-time Monitoring of cardiomyocyte activity in 48-well format
xCELLigence CardioECR, a high resolution system for the non-invasive, label-free real-time monitoring of cardiomyocyte activity in a 48-well format. The compact analyzer work station is put into the incubator, experiment control, data acquisition and evaluation is handled by the analyzer and a PC (laptop) located outside the incubator thus enabling continous data recording.


  • Cardiomyocyte activity and field potential measurement in real-time in 48-well E-Plates CardioECR 48
  • Rapid analysis cycles
  • Comprehensive and continous data recording throughout hole experiment (up to weeks)
  • Optimizes timing for compound application and/or downstream assays 
  • Excellent reproducibility and data integrity (<0.3% well failures, <15% intra/inter plate variation)
  • Fully automated data acquisition throughout the whole experiment
  • Long term experiments under controlled physiological conditions in the incubator
  • Compact design of work station, needs only very small space in incubator
  • Easy to handle, intuitive user interface for programming the test protocol
  • Data Analysis software integrated


For more information or Request a Demo, please contact us!

Cardiac Safety in Drug Development

The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative by the FDA seeks to develop a new paradigm for cardiac safety evaluation of new drugs that utilizes high throughput, predictive and mechanistic assays which can identify pro-arrhytmic compounds earlier in the drug discovery process. An important part of this initiative is to use cardiomyocyte model systems together with platforms that can provide incisive information on the pro-arrhythmic risk of compounds. reference:

Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety.Research Consortium. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Am Heart J.2014 Mar;167(3):292- 300.

Based on the succesful xCELLigence CARDIO, the development of the new xCELLigence CardioECR System was dedicated to optimization and accelaration of drug discovery processes.


Weiterführende Links zu "xCELLigence CardioECR"

Weitere Artikel von ACEA Biosciences Inc.
Ihr Ansprechpartner
E-Mail: josef.freund@ols-bio.de
T +49 421 276 16 9-0
M +49 160 989 33 113

CardioECR Work station

CardioECR Analyzer

CardioECR Control Unit